No abstract available.
Neuroleptic Malignant Syndrome*

We report a patient developed neuroleptic malignant syndrome (NMS) with myoglobulinemic acute renal failure and lithium intoxication due to lithium-olanzapine combination, who was successfully treated by hemodiafiltration. A 34-year-old woman with a 14-year history of bipolar disorder had been treated with lithium-olanzapine during last four days. She was admitted to our hospital for muscular rigidity, hyperthermia and altered consciousness. On admission, rhabdomyolsis was demonstratd by biochemical methods and serum level of lithium was 3.78 mEq/L which was far above toxic level. After the diagnosis of NMS with acute renal failure and lithium intoxication, olanzapine and lithium were discontinued and conservative measures and continuous venovenous hemodiafiltration were instituted. She recovered without any neurologic sequelae.
Female ; Humans ; Neuroleptic Malignant Syndrome

No abstract available.
Levodopa* ; Neuroleptic Malignant Syndrome* ; Parkinson Disease*

Neuroleptic malignant syndrome (NMS) is a fatal complication most often caused by an adverse reaction to neuroleptic or antipsychotic drugs, and is mostly brought out in the initial stage of medication. Late onset NMS after long term intake of neuroleptics is uncommon, and the neurochemical mechanism is undiscovered. We report a patient of late onset NMS after a long term intake of haloperidol who was successfully treated with dantrolene and bromocriptine.
Antipsychotic Agents ; Bromocriptine ; Dantrolene ; Haloperidol ; Humans ; Neuroleptic Malignant Syndrome

Aged ; Humans ; Male ; Neuroleptic Malignant Syndrome ; etiology ; physiopathology ; Parkinson Disease ; drug therapy ; Substance Withdrawal Syndrome

Neuroleptic malignant syndrome and serotonin syndrome share many common clinical features, and the term "Neurotoxic syndrome" can be used when a clear distinction cannot be made between the two. Here we present a case of 19-year-old man who experienced serotonin syndrome caused by sertraline intake, and consecutive neuroleptic malignant syndrome by risperidone. This case suggests that these two syndromes can be concomitantly induced in some patients who are susceptible to these drugs. Clinicians may have to pay close attention to this problem when prescribing drugs to patients who previously showed sensitivity to CNS-acting drugs.
Antipsychotic Agents ; Humans ; Neuroleptic Malignant Syndrome ; Risperidone* ; Serotonin Syndrome ; Sertraline* ; Young Adult

Neuroleptic malignant syndrome and serotonin syndrome share many common clinical features, and the term "Neurotoxic syndrome" can be used when a clear distinction cannot be made between the two. Here we present a case of 19-year-old man who experienced serotonin syndrome caused by sertraline intake, and consecutive neuroleptic malignant syndrome by risperidone. This case suggests that these two syndromes can be concomitantly induced in some patients who are susceptible to these drugs. Clinicians may have to pay close attention to this problem when prescribing drugs to patients who previously showed sensitivity to CNS-acting drugs.
Antipsychotic Agents ; Humans ; Neuroleptic Malignant Syndrome ; Risperidone* ; Serotonin Syndrome ; Sertraline* ; Young Adult

Clozapine, one of the dibenzodiazepine derivatives, has potent antipsychotic properties and acts on schizophrenic patients who are nonresponsive to classic neuroleptics without neurologic side effects such as extrapyamidal symptoms, tardive dyskinesia and neuroleptic malignant syndrome. But, several blood dyscrasias associated with clozapine are well known to clinicians. Potentially life-threatening agranulocytosis, leukopenia and leukocytosis are most widely reported. Also eosinophilia has been identified as a potential side effect in some studies or case reports. We report a case of severe eosinophilia associated with the administration of clozapine in a male schizophrenic patient, which improved spontaneously along with clozapine maintenance therapy. We also reviewed previous reports of eosinophilia induced by clozapine adminstration and recognized that eosinophilia is not uncommon and transient side effect of clozapine.
Agranulocytosis ; Antipsychotic Agents ; Clozapine* ; Eosinophilia* ; Humans ; Leukocytosis ; Leukopenia ; Male ; Movement Disorders ; Neuroleptic Malignant Syndrome ; Schizophrenia

We describe a case report of a young male patient with rhabdomyolysis associated with the use of atypical antipsychotic medication ziprasidone. A 23-year-old male was diagnosed with psychotic disorder not otherwise specified and treated with ziprasidone 120 mg a day. On hospital day 6, the patient developed acute dystonia. On day 8, the serum creatine kinase (CK) level was markedly elevated up to 53,880 IU/L, and a white blood cell (WBC) count was 10,500 cells/microliter. No other diagnostic criteria for neuroleptic malignant syndrome (NMS) were present. On discontinuation of the drug, serum CK concentrations returned to normal within 10 days. Atypical NMS should be considered when patients was treated with novel atypical antipsychotics who develop isolated serum CK elevation.
Antipsychotic Agents ; Creatine Kinase ; Dystonia ; Humans ; Leukocytes ; Male ; Neuroleptic Malignant Syndrome ; Psychotic Disorders ; Rhabdomyolysis* ; Young Adult

Risperidone is a relatively new antipsychotic agent. It is often referred to as 'atypical', because it has a mechanism of action that blocks post synaptic dopamine-2 and serotonin-2 receptors, it is associated with fewer extrapyramidal side effects, it is not yet associated with tardive dyskinesia, and it may have some efficacy on negative symptoms of schizophrenia. In despite of its 'atypical' nature, there are already more than 15 reports of risperidone-induced neuroleptic malignant syndrome. Only one case of risperidone-induced NMS was reported recently in Korea. We report one case of delayed risperidoneinduced neuroleptic malignant syndrome in young male patient and review the related articles.
Humans ; Korea ; Male ; Movement Disorders ; Neuroleptic Malignant Syndrome* ; Receptors, Serotonin, 5-HT2 ; Risperidone ; Schizophrenia